Clinical Trial Update: Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Control the Immune Hyperactivation Associated With COVID-19 and/or Acute Respiratory Distress Syndrome (THYTECH2) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating thymic tissue-derived regulatory T cells (thyTreg) to control immune hyperactivation in Systemic Inflammatory Response Syn…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Inflammatory Response Syndrome

Drugs mentioned

• thyTreg (thymic tissue-derived regulatory T cells)

Snippet

Sponsor: Hospital General Universitario Gregorio Marañon | Conditions: Systemic Inflammatory Response Syndrome | Phase 1, Phase 2 | Status: RECRUITING